Hinova Pharmaceuticals Inc. A
Hinova Pharmaceuticals Inc., a clinical-stage pharmaceutical company, engages in the development and production of therapeutics for cancers and metabolic syndromes. It develops drugs based on proteolysis targeting chimera and deuteration technology. The company's products pipeline includes HC-1119, a product in phase III clinical trials with castration resistant prostate cancer indications; HP501… Read more
Hinova Pharmaceuticals Inc. A (688302) - Total Assets
Latest total assets as of June 2025: CN¥1.39 Billion CNY
Based on the latest financial reports, Hinova Pharmaceuticals Inc. A (688302) holds total assets worth CN¥1.39 Billion CNY as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Hinova Pharmaceuticals Inc. A - Total Assets Trend (2019–2024)
This chart illustrates how Hinova Pharmaceuticals Inc. A’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Hinova Pharmaceuticals Inc. A - Asset Composition Analysis
Current Asset Composition (December 2024)
Hinova Pharmaceuticals Inc. A's total assets of CN¥1.39 Billion consist of 65.0% current assets and 35.0% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 46.5% |
| Accounts Receivable | CN¥0.00 | 0.0% |
| Inventory | CN¥4.56K | 0.0% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥30.56 Million | 2.2% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Hinova Pharmaceuticals Inc. A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Hinova Pharmaceuticals Inc. A's current assets represent 65.0% of total assets in 2024, a decrease from 89.2% in 2019.
- Cash Position: Cash and equivalents constituted 46.5% of total assets in 2024, up from 44.1% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 0.0% in 2019.
- Asset Diversification: The largest asset category is intangible assets at 2.2% of total assets.
Hinova Pharmaceuticals Inc. A Competitors by Total Assets
Key competitors of Hinova Pharmaceuticals Inc. A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Hinova Pharmaceuticals Inc. A - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Hinova Pharmaceuticals Inc. A generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Hinova Pharmaceuticals Inc. A is currently not profitable relative to its asset base.
Hinova Pharmaceuticals Inc. A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.55 | 7.21 | 4.72 |
| Quick Ratio | 7.54 | 7.21 | 4.72 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥879.45 Million | CN¥ 881.13 Million | CN¥ 683.82 Million |
Hinova Pharmaceuticals Inc. A - Advanced Valuation Insights
This section examines the relationship between Hinova Pharmaceuticals Inc. A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.65 |
| Latest Market Cap to Assets Ratio | 0.29 |
| Asset Growth Rate (YoY) | -8.7% |
| Total Assets | CN¥1.36 Billion |
| Market Capitalization | $399.12 Million USD |
Valuation Analysis
Below Book Valuation: The market values Hinova Pharmaceuticals Inc. A's assets below their book value (0.29 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Hinova Pharmaceuticals Inc. A's assets decreased by 8.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Hinova Pharmaceuticals Inc. A (2019–2024)
The table below shows the annual total assets of Hinova Pharmaceuticals Inc. A from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.36 Billion | -8.71% |
| 2023-12-31 | CN¥1.49 Billion | -14.03% |
| 2022-12-31 | CN¥1.74 Billion | +76.62% |
| 2021-12-31 | CN¥982.35 Million | -17.34% |
| 2020-12-31 | CN¥1.19 Billion | +2557.85% |
| 2019-12-31 | CN¥44.72 Million | -- |